Inflammatix is a molecular diagnostics company that is reimagining diagnostics by 'reading' the patient's immune system to deliver rapid results that improve patient care and reduce major public health burdens. The company's initial focus is on acute infection and sepsis, where its HostDx; tests combine proprietary biomarkers and advanced machine learning to help physicians quickly get the right treatments to the right patients. Each test will be developed to run on the company's sample-to-answer isothermal instrument platform in under 30 minutes, enabling the power of precision medicine at the point of care.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/10/20 | $32,000,000 | Series C |
Grey Sky Venture Partners Northpond Ventures Think.Health Ventures | undisclosed |
| 10/29/20 | $7,400,000 | Venture |
Biomedical Advanced Research and Development Authority | undisclosed |
| 09/12/24 | $57,000,000 | Series E |
D1 Capital Partners Iberis Capital Khosla Ventures  Northpond Ventures OSF Healthcare RAW Ventures Think.Health Ventures Vesalius Ventures | undisclosed |
